X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (25) 25
middle aged (14) 14
hematology (13) 13
male (11) 11
aged (10) 10
female (10) 10
life sciences (10) 10
adult (9) 9
multiple myeloma (9) 9
index medicus (8) 8
multiple myeloma - pathology (8) 8
oncology (8) 8
mesh : humans (7) 7
[ sdv.bbm ] life sciences [q-bio]/biochemistry, molecular biology (6) 6
article (6) 6
biochemistry, molecular biology (6) 6
interleukin-6 (6) 6
mesh : multiple myeloma (6) 6
mesh: humans (6) 6
[sdv.bbm]life sciences [q-bio]/biochemistry, molecular biology (5) 5
disease-free survival (5) 5
human multiple-myeloma (5) 5
immunology (5) 5
mesh: multiple myeloma (5) 5
multiple myeloma - genetics (5) 5
pathology (5) 5
prognosis (5) 5
aged, 80 and over (4) 4
antineoplastic agents - therapeutic use (4) 4
cancer (4) 4
cell differentiation (4) 4
expression (4) 4
malignant plasma-cells (4) 4
mesh : interleukin-6 (4) 4
metastasis (4) 4
monoclonal-antibody (4) 4
multiple-myeloma (4) 4
neoplasm staging (4) 4
plasma cells (4) 4
treatment outcome (4) 4
tumor cells, cultured (4) 4
tumor necrosis factor-alpha (4) 4
antibodies, monoclonal (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
apoptosis (3) 3
b-cell activating factor (3) 3
carcinoma, renal cell - drug therapy (3) 3
cell division (3) 3
chemotherapy (3) 3
everolimus (3) 3
follow-up studies (3) 3
france (3) 3
hematology, oncology and palliative medicine (3) 3
in-vitro (3) 3
indoles - therapeutic use (3) 3
interferon-alpha (3) 3
membrane proteins (3) 3
mesh : b-cell activating factor (3) 3
mesh : membrane proteins (3) 3
mesh : middle aged (3) 3
mesh: interleukin-6 (3) 3
mesh: middle aged (3) 3
metabolism (3) 3
multiple myeloma - metabolism (3) 3
nf-kappa-b (3) 3
plasma cells - metabolism (3) 3
pyrroles - therapeutic use (3) 3
remission induction (3) 3
stem cell transplantation (3) 3
survival (3) 3
therapy (3) 3
tumor necrosis factor (3) 3
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
[sdv.can]life sciences [q-bio]/cancer (2) 2
[sdv]life sciences [q-bio] (2) 2
administration & dosage (2) 2
adp-ribosyl cyclase (2) 2
adp-ribosyl cyclase 1 (2) 2
analysis (2) 2
antigens, cd (2) 2
antigens, cd34 (2) 2
antigens, differentiation - analysis (2) 2
antineoplastic agents/therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apoptosis - drug effects (2) 2
apoptosis - physiology (2) 2
biochemistry & molecular biology (2) 2
biological response modifiers (2) 2
biopsy (2) 2
bone marrow - pathology (2) 2
bone marrow cells - metabolism (2) 2
bone-marrow (2) 2
carcinoma, renal cell (2) 2
care and treatment (2) 2
cell biology (2) 2
cell line, tumor (2) 2
cell survival (2) 2
cells, cultured (2) 2
clinical-trials (2) 2
colony-stimulating factor (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 787 - 794
Journal Article
International Journal of Hematology, ISSN 0925-5710, 8/2003, Volume 78, Issue 2, pp. 106 - 113
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
Blood, ISSN 0006-4971, 04/2004, Volume 103, Issue 8, pp. 3148 - 3157
Identification of growth factors in neoplasias may be a target for future therapies by blocking either growth factor receptor interaction or the induced... 
B-LYMPHOCYTE STIMULATOR | TNF RECEPTOR | SYSTEMIC-LUPUS-ERYTHEMATOSUS | NECROSIS-FACTOR FAMILY | MATURATION PROTEIN | MONOCLONAL-ANTIBODY | GROWTH-FACTOR | MALIGNANT PLASMA-CELLS | HEMATOLOGY | NF-KAPPA-B | HUMAN MULTIPLE-MYELOMA | Interleukin-6 - antagonists & inhibitors | Apoptosis - drug effects | Humans | Tumor Necrosis Factor-alpha - genetics | Neuropeptides - physiology | RNA, Messenger - metabolism | RNA, Neoplasm - metabolism | Receptors, Tumor Necrosis Factor - physiology | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Membrane Proteins - physiology | Base Sequence | Plasma Cells - metabolism | Membrane Proteins - metabolism | Neuropeptides - genetics | Nuclear Proteins - genetics | Interleukin-6 - metabolism | Multiple Myeloma - physiopathology | Receptors, Tumor Necrosis Factor - genetics | Receptors, Tumor Necrosis Factor - metabolism | Gene Expression | Signal Transduction | Membrane Proteins - genetics | RNA, Messenger - genetics | Transmembrane Activator and CAML Interactor Protein | B-Cell Activation Factor Receptor | B-Cell Maturation Antigen | Multiple Myeloma - pathology | B-Cell Activating Factor | Tumor Necrosis Factor-alpha - physiology | Cell Line, Tumor | RNA, Neoplasm - genetics | Nuclear Proteins - physiology | Apoptosis - physiology | Multiple Myeloma - genetics | Dexamethasone | Hematology | Biochemistry, Molecular Biology | Neuropeptides | Nuclear Proteins | Interleukin-6 | Membrane Proteins | Life Sciences | Human health and pathology | Apoptosis | Multiple Myeloma | Cancer | pathology | RNA | Receptors | genetics | pharmacology | Tumor | Plasma Cells | Cell Line | drug therapy | physiology | drug effects | Messenger | Tumor Necrosis Factor-alpha | antagonists & inhibitors | Neoplasm | physiopathology | metabolism | Tumor Necrosis Factor
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2005, Volume 106, Issue 3, pp. 1021 - 1030
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 24, pp. 2585 - 2591
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2014, Volume 89, Issue 11, pp. 1024 - 1029
Treatment of primary central nervous system lymphoma (PCNSL) in elderly patients remains unsatisfactory. To develop a new high‐dose methotrexate (HD‐MTX)‐based... 
PRIMARY CNS LYMPHOMA | PILOT | INTENSIVE CHEMOTHERAPY | LEUKEMIA PATIENTS | THERAPY | PROGNOSIS | FOLLOW-UP | REGIMEN | RADIOTHERAPY | HEMATOLOGY | PROCARBAZINE | Prednisolone - adverse effects | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Palliative Care | Chemoradiotherapy | Infection - etiology | Dose-Response Relationship, Drug | Idarubicin - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Renal Insufficiency - chemically induced | Vindesine - adverse effects | Female | Idarubicin - administration & dosage | Immunocompetence | Neutropenia - chemically induced | Lymphoma, Non-Hodgkin - drug therapy | Lymphoma, Large B-Cell, Diffuse - drug therapy | Kaplan-Meier Estimate | Central Nervous System Neoplasms - therapy | Treatment Outcome | Thrombocytopenia - chemically induced | Remission Induction | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Vindesine - administration & dosage | Methotrexate - administration & dosage | Aged | Central Nervous System Neoplasms - drug therapy | Medical research | Anthracyclines | Corticosteroids | Central nervous system | Medicine, Experimental | Aged patients | Lymphomas | Methotrexate | Prednisolone | Index Medicus
Journal Article